ArticleBiological trace element research2026
Effect of Cu Nanoparticles Green-Formulated Using Allium sativum Extract Against Pseudomonas aeruginosa in Mice Lung Infection Model.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due mostly to the relative lack of effective chemotherapeutic methods, the lung infection incidence by Pseudomonas aeruginosa that are categorized as multi-drug resistant has significantly raised. This study demonstrated the strong antioxidant and anti-infectious properties of copper nanoparticles (CuNPs) made using an aqueous extract of Allium sativum in vivo. We employed FE-SEM, UV-Vis, XRD, EDX, and TEM to determine the characteristics of the CuNPs that were created when an aqueous extract of Allium sativum reacted with a copper nitrate solution. The fatal dosage of P. aeruginosa is assessed in mice as part of an in vivo investigation, and the clinical manifestations-such as bacteremia, hypothermia, and weight loss-are analyzed 48 h after infection. Infected mice's body temperature significantly decreased from 38.8 °C (0 h) to 32.5 °C (at 48 h), and after the trial, a 20% weight loss was noted. In comparison to day 1, when the bacterial burden was determined to be 1.5 Log10CFU/mL, the bacterial burden was 0.1 Log10CFU/mL on day 8, indicating a considerable decrease. According to histopathological findings, there was a more widespread and patchy buildup of alveolar space inflammatory cells, and infiltrates were seen in every lung segment of the infected animals. At 100 µg/kg, the research unequivocally states that the CuNPs is efficient on P. aeruginosa-induced lung infections. The lung infection histopathological scores of the group treated by the CuNPs were 0, 0, 1, and 1 related to the alveoli distortion and degeneration, inflammatory cell infiltration, congestion, and inflammatory cell infiltration, respectively. Following human clinical trials, the newly developed green-formulated copper particles may be administrated as a novel anti-infectious medication or dietary supplement.
Indexed as
Identifiers
41129018What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.